Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
25°
Mostly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Esperion Therapeutics, Inc. - Common Stock
(NQ:
ESPR
)
1.290
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Esperion Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 09, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Jefferies London Healthcare Conference
October 31, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Third Quarter 2023 Financial Results on November 7
October 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
5 Analysts Have This to Say About Esperion Therapeutics
August 02, 2023
Via
Benzinga
Analyst Expectations for Esperion Therapeutics's Future
June 26, 2023
Via
Benzinga
Analyst Ratings for Esperion Therapeutics
June 01, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
October 23, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 04, 2023
Via
Benzinga
"CLEAR" Progress At Esperion
September 16, 2023
Esperion Therapeutics, Inc. continues to showcase their positive CLEAR data, with two oral presentations at the European Society of Cardiology 2023 Congress. Here is a closer look at some highlights.
Via
Talk Markets
American College of Cardiology Program to Increase Cholesterol Screenings
September 12, 2023
From
Esperion Therapeutics, Inc.; The American College of Cardiology
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 30, 2023
Via
Benzinga
Why Is Esperion Therapeutics Stock Trading Higher Today?
August 28, 2023
Esperion Therapeutics Inc (NASDAQ: ESPR) announced the presentation of results from two CLEAR Outcomes Study Late-Breakers at the European
Via
Benzinga
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
August 26, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
August 11, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 08, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reports Second Quarter 2023 Financial Results
August 01, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in BTIG Virtual Biotechnology Conference 2023
July 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Second Quarter 2023 Financial Results on August 1
July 17, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
July 07, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
June 28, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
June 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
June 15, 2023
Cardiovascular risk reduction with bempedoic acid shown via the Cholesterol Treatment Trialists’ (CTT) Major Vascular Event endpoint is comparable to the normalized risk reduction with statins observed...
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
June 15, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 15, 2023
Via
Benzinga
Verastem To Rally Around 287%? Here Are 10 Other Analyst Forecasts For Thursday
June 15, 2023
Piper Sandler boosted the price target for Accenture plc (NYSE: ACN) from $250 to $316. Piper Sandler analyst Arvind Ramnani upgraded the stock from Underweight to Neutral. Accenture shares rose 1.1%...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
June 15, 2023
It's time to start breaking down the biggest pre-market stock movers for Thursday as we get ready for another busy day of trading!
Via
InvestorPlace
Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023
June 08, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
June 05, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
